» Articles » PMID: 35796885

Treatment Out-of-pocket Cost Communication and Remote Financial Navigation in Patients with Cancer: a Feasibility Study

Overview
Specialties Critical Care
Oncology
Date 2022 Jul 7
PMID 35796885
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We conducted a pilot study assessing the feasibility of a personalized out-of-pocket cost communication, remote financial navigation, and counseling (CostCOM) intervention in cancer patients.

Methods: Twenty-three adult, newly diagnosed cancer patients at a single community oncology practice were asked to complete a survey and participate in a CostCOM intervention, including patient-specific out-of-pocket cost communication, remote financial navigation, and counseling. Feasibility was defined as patient participation in CostCOM, and its impact on financial worry measured using the Comprehensive Score for Financial Toxicity (COST) (higher score = less worry) was assessed. Eight patients' and two providers' experience with CostCOM was evaluated using qualitative interviews.

Results: Mean patient age was 61 (78.3% female; 100% white). Of 23 CostCOM patients, 86.9% completed CostCOM, 60% of them completed a financial assistance application, and 25% of those who applied were enrolled in a co-pay assistance program. Patients' financial worry significantly improved following CostCOM (COST score of 10.0 ± 9.6 at enrollment vs. 16.9 ± 8.1 at follow-up; p < 0.001). Mean general satisfaction (out of 5) with CostCOM was 4.1 ± 0.7. In qualitative interviews following OOPC communication, 75% felt a positive impact on their mental health, and all patients reported no change in their treatment plan; 83.3% found financial navigation beneficial. In providers' interviews, buy-in from relevant stakeholders, integration of the CostCOM with existing workflow, and larger studies to assess the effectiveness of CostCOM were identified as factors needed for CostCOM implementation in practice.

Conclusion: CostCOM interventions are feasible and acceptable and decrease financial worry in patients with cancer.

Citing Articles

The Financial Toxicity Experience of Patients with Colorectal Cancer During Chemotherapy: A Qualitative Study.

Yao Y, Zhang S, Yu Q, Zhao X, Zhang X Curr Oncol. 2025; 32(1.

PMID: 39851939 PMC: 11764152. DOI: 10.3390/curroncol32010023.


A Costly Cure: Understanding and Addressing Financial Toxicity in Cardiovascular Disease Health Care Within the Domain of Social Determinants of Health.

Kandula V, Smith G, Rajaram R, Palaskas N, Deswal A, Nasir K Methodist Debakey Cardiovasc J. 2024; 20(5):15-26.

PMID: 39525372 PMC: 11546205. DOI: 10.14797/mdcvj.1466.


Impact of Virtual Navigation on the Education and Access of Patients with Cancer: A National Mixed Methods Investigation.

Haag S, Schaffer J SAGE Open Nurs. 2024; 10:23779608241281132.

PMID: 39380928 PMC: 11459495. DOI: 10.1177/23779608241281132.


Interventions to mitigate cancer-related medical financial hardship: A systematic review and meta-analysis.

Rashidi A, Jung J, Kao R, Nguyen E, Le T, Ton B Cancer. 2024; 130(18):3198-3209.

PMID: 38758809 PMC: 11347103. DOI: 10.1002/cncr.35367.


Interventions to Mitigate Financial Toxicity in Adult Patients with Cancer in the United States: A Scoping Review.

Villalona S, Castillo B, Chavez Perez C, Ferreira A, Nivar I, Cisneros J Curr Oncol. 2024; 31(2):918-932.

PMID: 38392062 PMC: 10888212. DOI: 10.3390/curroncol31020068.


References
1.
Zafar S, McNeil R, Thomas C, Lathan C, Ayanian J, Provenzale D . Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2014; 11(2):145-50. PMC: 4371118. DOI: 10.1200/JOP.2014.001542. View

2.
Altice C, Banegas M, Tucker-Seeley R, Yabroff K . Financial Hardships Experienced by Cancer Survivors: A Systematic Review. J Natl Cancer Inst. 2016; 109(2). PMC: 6075571. DOI: 10.1093/jnci/djw205. View

3.
Sinaiko A . What Is the Value of Market-Wide Health Care Price Transparency?. JAMA. 2019; 322(15):1449-1450. DOI: 10.1001/jama.2019.11578. View

4.
Wu S, Sylwestrzak G, Shah C, DeVries A . Price transparency for MRIs increased use of less costly providers and triggered provider competition. Health Aff (Millwood). 2014; 33(8):1391-8. DOI: 10.1377/hlthaff.2014.0168. View

5.
de Souza J, Yap B, Wroblewski K, Blinder V, Araujo F, Hlubocky F . Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2016; 123(3):476-484. PMC: 5298039. DOI: 10.1002/cncr.30369. View